DNA POLYMERASES WITH IMPROVED ACTIVITY
20180010106 · 2018-01-11
Inventors
- Keith Bauer (San Rafeal, CA, US)
- Thomas W. Myers (Los Altos, CA)
- Fred Reichert (San Leandro, CA)
- Shawn Suko (El Sobrante, CA)
Cpc classification
C12Y207/07049
CHEMISTRY; METALLURGY
C12N15/1096
CHEMISTRY; METALLURGY
C12N9/1252
CHEMISTRY; METALLURGY
International classification
Abstract
Disclosed are DNA polymerases having increased reverse transcriptase efficiency relative to a corresponding, unmodified polymerase. The polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the DNA polymerases.
Claims
1.-17. (canceled)
18. A DNA polymerase having increased reverse transcriptase efficiency, compared with a control DNA polymerase, wherein the DNA polymerase has at least 90% amino acid sequence identity to SEQ ID NO:6 and wherein the amino acid of the DNA polymerase corresponding to position 522 of SEQ ID NO:6 is any amino acid other than E, and wherein the control DNA polymerase has the same amino acid sequence as the DNA polymerase except that the amino acid of the control DNA polymerase corresponding to position 522 of SEQ ID NO:6 is E.
19. The DNA polymerase of claim 18, wherein the amino acid of the DNA polymerase corresponding to position 522 of SEQ ID NO:6 is selected from G, A, L, M, F, W, P, S, T, C, Y, Q, D, K, R, V, I, N, or H.
20. The DNA polymerase of claim 18, comprising a motif in the polymerase domain comprising S-T-X.sub.1-X.sub.2-X.sub.3-X.sub.4-L-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub.10-H-X.sub.11-I, wherein: X.sub.1 is S, R, N or A; X.sub.2 is A, I or V; X.sub.3 is A, E, S or D; X.sub.4 is V or A; X.sub.5 is any amino acid other than E; X.sub.6 is A, L, E, P or K; X.sub.7 is L or I; X.sub.8 is R, A or S; X.sub.9 is E, G, N, K, D or P; X.sub.10 is A, E, H or Y; X.sub.11 is P or E (SEQ ID NO:8).
21. The DNA polymerase of claim 20, wherein X.sub.5 is selected from G, A, L, M, F, W, P, S, T, C, Y, Q, D, K, R, V, I, N, or H.
22. The DNA polymerase of claim 18, comprising a motif in the polymerase domain comprising S-T-X.sub.1-X.sub.2-X.sub.3-V-L-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub.10-H-X.sub.11-I, wherein: X.sub.1 is S or R; X.sub.2 is A or I; X.sub.3 is A or E; X.sub.5 is any amino acid other than E; X.sub.6 is A, L or E; X.sub.7 is L or I; X.sub.8 is R or A; X.sub.9 is E, G or N; X.sub.10 is A or E; X.sub.11 is P or E. (SEQ ID NO:9).
23. The DNA polymerase of claim 18, comprising a motif in the polymerase domain comprising S-T-S-A-A-V-L-X.sub.5-A-L-R-E-A-H-P-I, wherein: X.sub.5 is any amino acid other than E (SEQ ID NO:10).
24. The DNA polymerase of claim 23, comprising a motif in the polymerase domain comprising S-T-S-A-A-V-L-X.sub.5-A-L-R-E-A-H-P-I, wherein: X.sub.5 is G (SEQ ID NO:11).
25. The DNA polymerase of claim 18, wherein the amino acid corresponding to position 580 of SEQ ID NO:6 is any amino acid other than D or E.
26. The DNA polymerase of claim 18, wherein the amino acid corresponding to position 580 of SEQ ID NO:6 is selected from the group consisting of L, G, T, Q, A, S, N, R, and K.
27. The DNA polymerase of claim 20, wherein the polymerase has at least 95% amino acid sequence identity to SEQ ID NO:6.
28. A recombinant nucleic acid encoding the DNA polymerase according to claim 18.
29. A method for conducting primer extension, comprising: contacting a DNA polymerase according to claim 1 with a primer, a polynucleotide template, and nucleoside triphosphates under conditions suitable for extension of the primer, thereby producing an extended primer.
30. The method of claim 31, wherein the template is RNA.
31. The method of claim 31, wherein the primer extension method comprises a polymerase chain reaction (PCR).
32. A kit for producing an extended primer, comprising: at least one container providing a DNA polymerase according to claim 18.
33. The kit according to claim 34, further comprising one or more additional containers selected from the group consisting of: (a) a container providing a primer hybridizable, under primer extension conditions, to a predetermined polynucleotide template; (b) a container providing nucleoside triphosphates; and (c) a container providing a buffer suitable for primer extension.
34. A reaction mixture comprising a DNA polymerase according to claim 18, at least one primer, a polynucleotide template, and nucleoside triphosphates.
35. The reaction mixture of claim 36, wherein the polynucleotide template is RNA.
36. The DNA polymerase of claim 18, wherein the polymerase has at least 95% amino acid sequence identity to SEQ ID NO:6.
37. An expression vector comprising the recombinant nucleic acid of claim 28.
38. A host cell transformed with the expression vector of claim 37.
39. A method for producing a DNA polymerase having increased reverse transcriptase efficiency compared with a control DNA polymerase, the method comprising culturing the host cell of claim 38 under conditions suitable for expression of the recombinant nucleic acid.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0103]
[0104] Figure provides sequence identities among the following DNA Polymerase I enzymes: Thermus sp. Z05 DNA polymerase (Z05), Thermus aquaticus DNA polymerase (Taq); Thermus filiformis DNA polymerase (Tfi); Thermus flavus DNA polymerase (Tfl); Thermus sp. Sps17DNA polymerase (Sps17); Thermus thermophiles DNA polymerase (Tth); Thermus caldophilus DNA polymerase (Tca); Deinococcus radiodurans DNA polymerase (Dra); Thermotoga maritima DNA polymerase (Tma); Thermotoga neopolitana DNA polymerase (Tne); Thermusipho africanus DNA polymerase (Tat); Bacillus stearothermophilus DNA polymerase (Bst); and Bacillus caldotenax DNA polymerase (Bca). (A) sequence identities over the entire polymerase I enzyme (corresponding to amino acids 1-834 of Z05); and (B) sequence identities over the polymerase sub domain corresponding to amino acids 420-834 of Z05.
[0105]
DETAILED DESCRIPTION
[0106] The present invention provides improved DNA polymerases in which one or more amino acids in the polymerase domain have been mutated relative to a functional DNA polymerase. The DNA polymerases of the invention are active enzymes having increased reverse transcriptase efficiency (e.g., in the presence of Mn.sup.2+ and Mg.sup.2+ divalent cations) relative to the unmodified form of the polymerase. In certain embodiments, the mutant DNA polymerases may be used at lower concentrations for superior or equivalent performance as the parent enzymes.
[0107] DNA polymerases that more efficiently perform reverse transcription are helpful, for example, in a variety of applications involving assays that employ RT-PCR to detect and/or quantify RNA targets. The DNA polymerases are therefore useful in a variety of applications involving polynucleotide extension as well as reverse transcription or amplification of polynucleotide templates, including, for example, applications in recombinant DNA studies and medical diagnosis of disease. The mutant DNA polymerases are also particularly useful, because of their tolerance for mis-matches, for detecting targets that possibly have variable sequences (e.g., viral targets, or cancer and other disease genetic markers).
[0108] In some embodiments, DNA polymerases of the invention can he characterized by having the following motif: [0109] Ser-Thr-X.sub.1-X.sub.2-X.sub.3-X.sub.4-Leu-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub.10-His-X.sub.11-Ile (also referred to herein in the one-letter code as S-T-X.sub.1-X.sub.2-X.sub.3-X.sub.4-L-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub.10-H-X.sub.11-I) (SEQ ID NO:8); wherein [0110] X.sub.1 is Ser (S), Arg (R), Asn (N) or Ala (A); [0111] X.sub.2 is Ala (A), Ile (I) or Val (V); [0112] X.sub.3 is Ala (A), Glu (E), Ser (S) or Asp (D); [0113] X.sub.4 is Val (V) or Ala (A); [0114] X.sub.5 is any amino acid other than Glu (E); [0115] X.sub.6 is Ala (A), Leu (L), Glu (E), Pro (P) or Lys (K); [0116] X.sub.7 is Len (L) or Ile (I); [0117] X.sub.8 is Arg (R), Ala (A) or Ser (S); [0118] X.sub.9 is Glu (E), Gly (G), Asn (N), Lys (K), Asp (D) or Pro (P); [0119] X.sub.10 is Ala (A), Gln (E), His (H) or Tyr (Y); [0120] X.sub.11 is Pro (P) or Glu (E).
[0121] In some embodiments, X.sub.5 is selected from G, A, L, M, F, W, P, S, T, C, Y, Q, D, K, R, V, I, N, or H.
[0122] In some embodiments, DNA polymerases of the invention can be having the following motif (corresponding to Thermus and Thermotoga): [0123] Ser-Thr-X.sub.1-X.sub.2-X.sub.3-Val-Leu-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub.10-His-X.sub.11-Ile (also referred to herein in the one-letter code as S-T-X.sub.1-X.sub.2-X.sub.3-V-L-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub.10-H-X.sub.11-I) (SEQ ID NO:9); wherein [0124] X.sub.1 is Ser (S) or Arg (R); [0125] X.sub.2 is Ala (A) or Ile (I); [0126] X.sub.3 is Ala (A) or Glu (E); [0127] X.sub.5 is any amino acid other than Glu (E); [0128] X.sub.6 is Ala (A), Leu (L) or Glu (E); [0129] X.sub.7 is Leu (L) or Ile (I); [0130] X.sub.8 is Arg (R) or Ala (A); [0131] X.sub.9 is Glu (E), Gly (G) or Asn (N); [0132] X.sub.10 is Ala (A) or Glu (E); [0133] X.sub.11 is Pro (P) or Glu (E).
[0134] In some embodiments, DNA polymerases of the invention can be having the following motif:
[0135] Ser-Thr-Ser-Ala-Ala-Val-Leu-X.sub.5-Ala-Leu-Arg-Glu-Ala-His-Pro-Ile (also referred to herein in the one-letter code as S-T-S-A-A-V-L-X.sub.5-A-L-R-E-A-H-P-I) (SEQ D NO:10); wherein [0136] X.sub.5 is any amino acid other than Glu (E).
[0137] In some embodiments, DNA polymerases of the invention can be characterized by having the following motif: [0138] Ser-Thr-Ser-Ala-Ala-Val-Leu-X.sub.5Ala-Leu-Arg-Glu-Ala-His-Pro-Ile (also referred to herein in the one-letter code as S-T-S-A-A-V-L-X.sub.5-A-L-R-E-A-H-P-I) (SEQ D NO:11); wherein X.sub.5 is Gly (G).
[0139] This motif is present within the “thumb” domain of many Family A type DNA-dependent DNA polymerases, particularly thermostable DNA polymerases from thermophilic bacteria (Li et al., EMBO J. 17:7514-7525, 1998). For example,
[0140] Accordingly, in some embodiments, the invention provides for a polymerase comprising SEQ ID NO:8, 9, 10, or 11, having the improved activity and/or characteristics described herein, and wherein the DNA polymerase is otherwise a wild-type or a naturally occurring DNA polymerase, such as, for example, a polymerase from any of the species of thermophilic bacteria listed above, or is substantially identical to such a wild-type or a naturally occurring DNA polymerase. For example, in some embodiments, the polymerase of the invention comprises SEQ ID NO:8, 9, 10, or 11 and is at least 80%, 85%, 90%, or 95% identical to SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 32, 33, 34, 35, 36, 37, or 40. In one variation, the unmodified form of the polymerase is from a species of the genus Thermus. In other embodiments of the invention, the unmodified polymerase is from a thermophilic species other than Thermus, e.g., Thermotoga. The full nucleic acid and amino acid sequence for numerous thermostable DNA polymerases are available. The sequences each of Thermus aquaticus (Taq) (SEQ ID NO:2), Thermus thermophilus (Tth) (SEQ ID NO:6), Thermus species Z05 (SEQ ID NO:1), Thermus species Sps17 (SEQ ID NO:5), Thermotoga maritima (Tma) (SEQ ID NO:34), and Thermusipho africanus (Taf) (SEQ ID NO:33) polymerase have been published in PCT International Patent Publication No. WO 92/06200, which is incorporated herein by reference. The sequence for the DNA polymerase from Thermus flavus (SEQ ID NO:4) has been published in Akhmetzjanov and Vakhitov (Nucleic Acids Research 20:5839, 1992), which is incorporated herein by reference. The sequence of the thermostable DNA polymerase from Thermus caldophilus (SEQ ID NO:7) is found in EMBL/GenBank Accession No. U62584. The sequence of the thermostable DNA polymerase from Thermus filiformis can be recovered from ATCC Deposit No. 42380 using, e.g., the methods provided in U.S. Pat. No. 4,889,818, as well as the sequence information provided in Table 1. The sequence of the Thermotoga neapolitana (Tne) DNA polymerase (SEQ ID NO:35) is from GeneSeq Patent Data Base Accession No. 898144 and PCT WO 97/09451, each incorporated herein by reference. The sequence of the thermostable DNA polymerase from Bacillus caldotenax (SEQ ID NO:37 is described in, e.g., Uemori et al. (J Biochem (Tokyo) 113(3):401-410, 1993; see also, Swiss-Prot database Accession No. Q04957 and GenBank Accession Nos. D12982 and BAA02361), which are each incorporated by reference. Examples of unmodified forms of DNA polymerases that can be modified as described herein are also described in, e.g., U.S. Pat. Nos. 6,228,628, entitled “Mutant chimeric DNA polymerase” issued May 8, 2001 to Gelfand et al.; 6,346,379, entitled “Thermostable DNA polymerases incorporating nucleoside triphosphates labeled with fluorescein family dyes” issued Feb. 12, 2002 to Gelfand et al.; 7,030,220, entitled “Thermostable enzyme promoting the fidelity of thermostable DNA polymerases-for improvement of nucleic acid synthesis and amplification in vitro” issued Apr. 18, 2006 to Ankenbauer et al.; 6,881,559 entitled “Mutant B-type DNA polymerases exhibiting improved performance in PCR” issued Apr. 19, 2005 to Sobek et al.; 6,794,177 entitled “Modified DNA-polymerase from carboxydothermus hydrogenoformans and its use for coupled reverse transcription and polymerase chain reaction” issued Sep. 21, 2004 to Markau et al.; 6,468,775, entitled “Thermostable DNA polymerase from carboxydothermus hydrogenoformans” issued Oct. 22, 2002 to Ankenbauer et al.; and U.S. Pat. Nos. 7,148,049 entitled “Thermostable or thermoactive DNA polymerase molecules with attenuated 3′-5′ exonuclease activity” issued Dec. 12, 2006 to Schoenbrunner et al.; 7,179,590 entitled “High temperature reverse transcription using mutant DNA polymerases” issued Feb. 20, 2007 to Smith et al.; 7,410,782 entitled “Thermostable enzyme promoting the fidelity of thermostable DNA polymerases-for improvement of nucleic acid synthesis and amplification in vitro” issued Aug. 12, 2008 to Ankenbauer et al; 7,378,262 entitled “Reversibly modified thermostable enzymes for DNA synthesis and amplification in vitro” issued May 27, 2008 to Sobek et al., which are each incorporated by reference. Representative full length polymerase sequences are also provided in the Sequence Listing. For example, Deinococcus radiodurans DNA polymerase (Dra) is shown as SEQ ID NO:32.
[0141] Also amenable to the mutations described herein are functional DNA polymerases that have been previously modified (e.g., by amino acid substitution, addition, or deletion). In some embodiments, such functional modified polymerases retain the amino acid motif of SEQ ID NO:8 (or a motif of SEQ ID NO:9, 10 or 11), and optionally the amino acid motif of SEQ ID NO:38. Thus, suitable unmodified DNA polymerases also include functional variants of wild-type or naturally occurring polymerases. Such variants typically will have substantial sequence identity or similarity to the wild-type or naturally occurring polymerase, typically at least 80% sequence identity and more typically at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity.
[0142] In some embodiments, the polymerase of the invention, as well as having a polymerase domain comprising SEQ NOS:8, 9, 10, or 11 also comprises a nuclease domain (e.g., corresponding to positions 1 to 291 of Z05)
[0143] In some embodiments, a polymerase of the invention is a chimeric polymerase, i.e., comprising polypeptide regions from two or more enzymes. Examples of such chimeric DNA polymerases are described in, e.g., U.S. Pat. No. 6,228,628, which is incorporated by reference herein in its entirety. Particularly suitable are chimeric CS-family DNA polymerases, which include the CS5 (SEQ ID NO:27) and CS6 (SEQ ID NO:28) polymerases and variants thereof having substantial amino acid sequence identity or similarity to SEQ ID NO:27 or SEQ ID NO:28 (typically at least 80% amino acid sequence identity and more typically at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity) and can thus be modified to contain SEQ ID NO:8. The CS5 and CS6 DNA polymerases are chimeric enzymes derived from Thermus sp. Z05 and Thermotoga Maritillia (Tma) DNA polymerases. They comprise the N-terminal 5′-nuclease domain of the Thermus enzyme and the C-terminal 3′-5′ exonuclease and the polymerase domains of the Tma enzyme. These enzymes have efficient reverse transcriptase activity, can extend nucleotide analog-containing primers, and can incorporate alpha-phosphorothioate dNTPs, dUTP, dITP, and also fluorescein- and cyanine-dye family labeled dNTPs, The CS5 and CS6 polymerases are also efficient Mg.sup.2+-activated PCR enzymes. The CS5 and CS6 chimeric polymerases are further described in, e.g., U.S. Pat. No. 7,148,049, which is incorporated by reference herein in its entirety.
[0144] In some embodiments, the amino acid substitutions are single amino acid substitutions. The DNA polymerases provided herein can comprise one or more amino acid substitutions in the active site relative to the unmodified polymerase. In some embodiments, the amino acid substitution(s) comprise at least position X.sub.5 of the motif set forth in SEQ ID NO:8 (or a motif of SEQ ID NO:9, 10 or 11), Amino acid substitution at this position confers increased reverse transcriptase efficiency, yielding a mutant DNA polymerase with an increased reverse transcriptase efficiency relative to the unmodified polymerase. Typically, the amino acid at position X.sub.5 is substituted with an amino acid that does not correspond to the native sequence within the motif set forth in SEQ ID NO:8 (or a motif of SEQ ID NO:9, 10 or 11). Thus, typically, the amino acid at position X.sub.5, if substituted, is not Glu (E) as this position occurs in naturally-occurring polymerases. See, e.g.,
[0145] In some embodiments, the polymerase of the invention comprises SEQ ID NO:8, 9, 10, or 11 and further comprises one or more additional amino acid changes (e.g., by amino acid substitution, addition, or deletion) compared to a native polymerase. In some embodiments, such polymerases retain the amino acid motif of SEQ ID NO8 (or a motif of SEQ ID NO:9, 10 or 11), and further comprise the amino acid motif of SEQ ID NO:38 (corresponding to the D580X mutation of Z05 (SEQ ID NO:1)) as follows: [0146] Thr-Gly-Arg-Leu-Ser-Ser-X.sub.7-X.sub.8-Pro-Asn-Leu-Gln-Asn (also referred to herein in the one-letter code as T-G-R-L-S-S-X.sub.7-X.sub.8-P-N-L-Q-N) (SEQ ID NO:38); wherein [0147] X.sub.7 is Ser (S) or Thr (T) and [0148] X.sub.8 is any amino acid other than Asp (D) or Glu (E)
The mutation characterized by SEQ ID NO:38 is discussed in more detail in, e.g., U.S. Patent Publication No. 2009/0148891. Such functional variant polymerases typically will have substantial sequence identity or similarity to the wild-type or naturally occurring polymerase (e.g., SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 32, 33, 34, 35, 36, 37, or 40), typically at least 80% amino acid sequence identity and more typically at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% amino acid sequence identity.
[0149] In some embodiments, the DNA polymerase of the invention comprises an amino acid substitution at position X.sub.5 (e.g., as in a motif selected from SEQ ID NO:8, 9, 10 or 11) and comprises an amino acid substitution corresponding to SEQ ID NO:38.
[0150] Other suitable amino acid substitution(s) at one or more of the identified sites can be determined using, e.g., known methods of site-directed mutagenesis and determination of polynucleotide extension performance in assays described further herein or otherwise known to persons of skill in the art, e.g., amino acid substitutions described in U.S. Pat. Application Publication Nos. 2009/0148891 and 2009/0280539, which are incorporated by reference herein in its entirety.
[0151] Because the precise length of DNA polymerases vary, the precise amino acid positions corresponding to each of X.sub.5 of SEQ ID NOS:8, 9, 10 or 11 or X.sub.8 of SEQ ID NO:38 can vary depending on the particular mutant polymerase used. Amino acid and nucleic acid sequence alignment programs are readily available (see, e.g., those referred to supra) and, given the particular motifs identified herein, serve to assist in the identification of the exact amino acids (and corresponding codons) for modification in accordance with the present invention. The positions corresponding to each of X.sub.5 and X.sub.8 are shown in Table 1 for representative chimeric thermostable DNA polymerases and thermostable DNA polymerases from exemplary thermophilic species.
TABLE-US-00001 TABLE 1 Amino Acid Positions Corresponding to Motif Positions X.sub.5 (e.g., of SEQ ID NOS: 8, 9, 10, and 11) and X.sub.8 (of SEQ ID NO: 38) in Exemplary Polymerases. Amino Acid Position Organism or Chimeric Sequence X.sub.8 (of SEQ ID Consensus (SEQ ID NO:) X.sub.5 NO: 38) T. thermophilus (6) 522 580 T. caldophilus (7) 522 580 T. sp. Z05 (1) 522 580 T. aquaticus (2) 520 578 T. flavus (4) 519 577 T. filiformis (3) 518 576 T. sp. Sps17 (5) 518 576 T. maritima (34) 582 640 T. neapolitana (35) 582 640 T. africanus (33) 581 639 B. caldotenax (37) 562 621 B. stearothermophilus (36) 562 620 CS5 (27) 582 640 CS6 (28) 582 640 D. radiodurans (32) 610 668
[0152] In some embodiments, the DNA polymerase of the present invention is derived from Thermus sp. Z05 DNA polymerase (SEQ ID NO:1) or a variant thereof (e.g., carrying the D580G mutation or the like). As referred to above, in Thermus sp. Z05 DNA polymerase, position X.sub.5 corresponds to Glutamic acid (E) at position 522; position X.sub.8 corresponds to Aspartate (D) at position 580. Thus, in certain variations of the invention, the mutant polymerase comprises at least one amino acid substitution, relative to a Thermus sp. Z05 DNA polymerase, at E522 and/or D580. Thus, typically, the amino acid at position 522 is not E. In some embodiments, the amino acid at position 522 is selected from G, A, L, M, F, W, P, S, T, C, Y, Q, D, K, R, V, I, N, or H. In some embodiments, the amino acid at the position corresponding to position 552 of SEQ ID NO:1 is an amino acid having a nonpolar, uncharged side chain (e.g., G, A, L, M, W, P, F, C, V, or I) at neutral pH. In certain embodiments, the amino acid residue at position 522 is G. In certain embodiments, amino acid residues at position D580 can be selected from Leucine (L), Glycine (G), Threonine (T), Glutamine (Q), Alanine (A), Serine (S), Asparagine (N), Arginine (R), and Lysine (K).
[0153] Exemplary Thermus sp. Z05 DNA polymerase mutants include those comprising the amino acid substitution(s) E522G and/or D580G. In sonic embodiments, the mutant Thermus sp. Z05 DNA polymerase comprises, e.g., amino acid residue substitutions E552G and D580G. In certain embodiments, the mutant Thermus sp. Z05 DNA polymerase comprises, e.g., amino acid residue substitutions independently selected from E522G and/or D580G.
[0154] In addition to mutation of the motifs of SEQ ID NOS:8, 9, 10, 11, and 38 as described herein, the DNA polymerases of the present invention can also include other, non-substitutional modification(s). Such modifications can include, for example, covalent modifications known in the art to confer an additional advantage in applications comprising polynucleotide extension. For example, one such modification is a thermally reversible covalent modification that inactivates the enzyme, but which is reversed to activate the enzyme upon incubation at an elevated temperature, such as a temperature typically used for polynucleotide extension. Exemplary reagents for such thermally reversible modifications are described in U.S. Pat. Nos. 5,773,258 and 5,677,152 to Birch et al., which are expressly incorporated by reference herein in their entirety.
[0155] The DNA polymerases of the present invention can be constructed by mutating the DNA sequences that encode the corresponding unmodified polymerase (e.g., a wild-type polymerase or a corresponding variant from which the polymerase of the invention is derived), such as by using techniques commonly referred to as site-directed mutagenesis. Nucleic acid molecules encoding the unmodified form of the polymerase can be mutated by a variety of polymerase chain reaction (PCR) techniques well-known to one of ordinary skill in the art. (See, e.g., PCR Strategies (M. A. Innis, D. H. Gelfand, and J. J. Sninsky eds., 1995, Academic Press, San Diego, Calif.) at Chapter 14; PCR Protocols. A Guide to Methods and Applications (M. A. Innis, D. H. Gelfand, J. J. Sninsky, and T. J. White eds., Academic Press, NY, 1990),
[0156] By way of non-limiting example, the two primer system, utilized in the Transformer Site-Directed Mutagenesis kit from Clontech, may be employed for introducing site-directed mutants into a polynucleotide encoding an unmodified form of the polymerase. Following denaturation of the target plasmid in this system, two primers are simultaneously annealed to the plasmid; one of these primers contains the desired site-directed mutation, the other contains a mutation at another point in the plasmid resulting in elimination of a restriction site. Second strand synthesis is then carried out, tightly linking these two mutations, and the resulting plasmids are transformed into a mutS strain of E. coli. Plasmid DNA is isolated from the transformed bacteria, restricted with the relevant restriction enzyme (thereby linearizing the unmutated plasmids), and then retransformed into E. coli. This system allows for generation of mutations directly in an expression plasmid, without the necessity of subcloning or generation of single-stranded phagemids. The tight linkage of the two mutations and the subsequent linearization of unmutated plasmids result in high mutation efficiency and allow minimal screening. Following synthesis of the initial restriction site primer, this method requires the use of only one new primer type per mutation site. Rather than prepare each positional mutant separately, a set of “designed degenerate” oligonucleotide primers can be synthesized in order to introduce all of the desired mutations at a given site simultaneously. Transformants can be screened by sequencing the plasmid DNA through the mutagenized region to identify and sort mutant clones. Each mutant DNA can then be restricted and analyzed by electrophoresis, such as for example, on a Mutation Detection Enhancement gel (Mallinckrodt Baker, Inc., Phillipsburg, N.J.) to confirm that no other alterations in the sequence have occurred (by band shift comparison to the unmutagenized control). Alternatively, the entire DNA region can be sequenced to confirm that no additional mutational events have occurred outside of the targeted region.
[0157] DNA polymerases with more than one amino acid substituted can be generated in various ways. In the case of amino acids located close together in the polypeptide chain, they may be mutated simultaneously using one oligonucleotide that codes for all of the desired amino acid substitutions. If however, the amino acids are located some distance from each other (separated by more than ten amino acids, for example) it is more difficult to generate a single oligonucleotide that encodes all of the desired changes. Instead, one of two alternative methods may be employed. In the first method, a separate oligonucleotide is generated for each amino acid to be substituted. The oligonucleotides are then annealed to the single-stranded template DNA simultaneously, and the second strand of DNA that is synthesized from the template will encode all of the desired amino acid substitutions. An alternative method involves two or more rounds of mutagenesis to produce the desired mutant. The first round is as described for the single mutants: DNA encoding the unmodified polymerase is used for the template, an oligonucleotide encoding the first desired amino acid substitution(s) is annealed to this template, and the heteroduplex DNA molecule is then generated. The second round of mutagenesis utilizes the mutated DNA produced in the first round of mutagenesis as the template. Thus, this template already contains one or more mutations. The oligonucleotide encoding the additional desired amino acid substitution(s) is then annealed to this template, and the resulting strand of DNA now encodes mutations from both the first and second rounds of mutagenesis. This resultant DNA can be used as a template in a third round of mutagenesis, and so on. Alternatively, the multi-site mutagenesis method of Seyfang & Jin (Anal. Biochem. 324:285-291. 2004) may be utilized.
[0158] Accordingly, also provided are recombinant nucleic acids encoding any of the DNA polymerases of the present invention. Using a nucleic acid of the present invention, encoding a DNA polymerase, a variety of vectors can be made. Any vector containing replicon and control sequences that are derived from a species compatible with the host cell can be used in the practice of the invention. Generally, expression vectors include transcriptional and translational regulatory nucleic acid regions operably linked to the nucleic acid encoding the DNA polymerase. The term “control sequences” refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. In addition, the vector may contain a Positive Retroregulatory Element (PRE) to enhance the half-life of the transcribed mRNA (see Gelfand et al. U.S. Pat. No. 4,666,848). The transcriptional and translational regulatory nucleic acid regions will generally be appropriate to the host cell used to express the polymerase. Numerous types of appropriate expression vectors, and suitable regulatory sequences are known in the art for a variety of host cells. In general, the transcriptional and translational regulatory sequences may include, e.g., promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. In typical embodiments, the regulatory sequences include a promoter and transcriptional start and stop sequences. Vectors also typically include a polylinker region containing several restriction sites for insertion of foreign DNA. In certain embodiments, “fusion flags” are used to facilitate purification and, if desired, subsequent removal of tag/flag sequence, e.g., “His-Tag”. However, these are generally unnecessary' when purifying a thermoactive and/or thermostable protein from a mesophilic host (e.g., E. coli) where a “heat-step” may be employed. The construction of suitable vectors containing DNA encoding replication sequences, regulatory sequences, phenotypic selection genes, and the polymerase of interest are prepared using standard recombinant DNA procedures. Isolated plasmids, viral vectors, and DNA fragments are cleaved, tailored, and ligated together in a specific order to generate the desired vectors, as is well-known in the art (see, e.g., Sambrook et al. Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory Press, New York, N.Y., 2nd ed. 1989)).
[0159] In certain embodiments, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used. Suitable selection genes can include, for example, genes coding for ampicillin and/or tetracycline resistance, which enables cells transformed with these vectors to grow in the presence of these antibiotics.
[0160] In one aspect of the present invention, a nucleic acid encoding a DNA polymerase is introduced into a cell, either alone or in combination with a vector. By “introduced into” or grammatical equivalents herein is meant that the nucleic acids enter the cells in a manner suitable for subsequent integration, amplification, and/or expression of the nucleic acid. The method of introduction is largely dictated by the targeted cell type. Exemplary methods include CaPO.sub.4 precipitation, liposome fusion, LIPOFECTIN®, electroporation, viral infection, and the like.
[0161] In some embodiments, prokaryotes are typically used as host cells for the initial cloning steps of the present invention. They are particularly useful for rapid production of large amounts of DNA, for production of single-stranded DNA templates used for site-directed mutagenesis, for screening many mutants simultaneously, and for DNA sequencing of the mutants generated. Suitable prokaryotic host cells include E. coli K12 strain 94 (ATCC No. 31,446), E. coli strain W3110 (ATCC No. 27,325), E. coli K12 strain DG116 (ATCC No. 53,606), E. coli X1776 (ATCC No. 31,537), and E. coli B; however many other strains of E. coli, such as HB 101, JM101, NM522, NM538, NM539, and many other species and genera of prokaryotes including bacilli such as Bacillus subtilis, other enterobacteriaceae such as Salmonella typhimurium or Serratia marcesans, and various Pseudomonas species can all be used as hosts. Prokaryotic host cells or other host cells with rigid cell walls are typically transformed using the calcium chloride method as described in section 1.82 of Sambrook et al., supra. Alternatively, electroporation can be used for transformation of these cells. Prokaryote transformation techniques are set forth in, for example Dower, in Genetic Engineering, Principles and Methods 12:275-296 (Plenum Publishing Corp., 1990); Hanahan et al., Meth. Enzymol., 204:63, 1991. Plasmids typically used for transformation of E. coli include pBR322, pUCI8, pUCI9, pUCI18, pUC119, and Bluescript M13, all of which are described in sections 1.12-1.20 of Sambrook et al., supra. However, many other suitable vectors are available as well.
[0162] The DNA polymerases of the present invention are typically produced by culturing a host cell transformed with an expression vector containing a nucleic acid encoding the DNA polymerase, under the appropriate conditions to induce or cause expression of the DNA polymerase. Methods of culturing transformed host cells under conditions suitable for protein expression are well-known in the art (see, e.g., Sambrook et al., supra). Suitable host cells for production of the polymerases from lambda pL promotor-containing plasmid vectors include coli strain DG116 (ATCC No. 53606) (see U.S. Pat. No. 5,079,352 and Lawyer, F. C. et al., PCR Methods and Applications 2:275-87, 1993, which are both incorporated herein by reference) Following expression, the polymerase can be harvested and isolated. Methods for purifying the thermostable DNA polymerase are described in, for example, Lawyer et al., supra. Once purified, the ability of the DNA polymerases to have improved RT efficiency, increased mis-match tolerance, extension rate and/or tolerance of RT and polymerase inhibitors can be tested (e.g., as described in the examples).
[0163] The improved DNA polymerases of the present invention may be used for any purpose in which such enzyme activity is necessary or desired. Accordingly, in another aspect of the invention, methods of polynucleotide extension (e.g., PCR) using the polymerases are provided. Conditions suitable for polynucleotide extension are known in the art. (See, e.g., Sambrook et al., supra. See also Ausubel et al., Short Protocols in Molecular Biology (4th ed., John Wiley & Sons 1999). Generally, a primer is annealed, i.e., hybridized, to a target nucleic acid to form a primer-template complex. The primer-template complex is contacted with the DNA polymerase and nucleoside triphosphates in a suitable environment to permit the addition of one or more nucleotides to the 3′ end of the primer, thereby producing an extended primer complementary to the target nucleic acid. The primer can include, e.g., one or more nucleotide analog(s). In addition, the nucleoside triphosphates can be conventional nucleotides, unconventional nucleotides (e.g., ribonucleotides or labeled nucleotides), or a mixture thereof. In some variations, the polynucleotide extension reaction comprises amplification of a target nucleic acid. Conditions suitable for nucleic acid amplification using a DNA polymerase and a primer pair are also known in the art (e.g., PCR amplification methods). (See, e.g., Sambrook et al., supra; Ausubel et al., supra; PCR Applications: Protocols for Functional Genomics (Innis et al. eds., Academic Press 1999). In other, non-mutually exclusive embodiments, the polynucleotide extension reaction comprises reverse transcription of an RNA template (e.g., RT-PCR). In some embodiments, the improved polymerases find use in 454 sequencing (Margulies, M et al. 2005, Nature, 437, 376-380).
[0164] In some embodiments, an improved polymerase of the invention is used in a reverse transcription reaction. In some embodiments, the reverse transcription reaction is carried out in a mixture containing the RNA template, one or more primer(s), and a thermostable DNA polymerase of the invention. The reaction mixture typically contains all four standard deoxyribonucleoside triphosphates (dNTPs) and a buffer containing a divalent cation and a monovalent cation. Exemplary cations include, e.g., Mg.sup.2+, although other cations, such as Mn.sup.2+ or Co.sup.2+ can activate DNA polymerases. In other embodiments, the reverse transcription reaction is carried out with a thereto-active DNA polymerase of the invention. In particular embodiments, the improved polymerase of the invention allows for more efficient amplification of RNA templates without compromising the efficient amplification of a DNA template in the presence of Mn.sup.2+ or Mg.sup.2+, as described in the examples.
[0165] The most efficient RT activity in thermostable DNA polymerases has been achieved using Mn.sup.2+ as the divalent metal ion activator. However, it is well known that when Mn.sup.2+ is present in reactions the fidelity of DNA polymerases is lower. Unless one is trying to generate mutations, it is generally favored to maintain a higher fidelity. Fortunately, most conventional sequencing, PCR and RT-PCR applications do not require high fidelity conditions because the detection systems generally are looking at a population of products. With the advent of next generation sequencing, digital PCR, etc., the fidelity of the product is more important and methods that allow for higher fidelity DNA synthesis are critical. Achieving efficient RT activity using Mg.sup.2+ as the divalent metal ion activator is an excellent way to substantially increase the fidelity of the DNA polymerase and allow for more reliable copying of the nucleic acid target.
[0166] Because the polymerases described herein can also have increased mismatch tolerance, the polymerases find use in methods where variation of the target template is likely and yet the template is nevertheless desired to be amplified regardless of the variation at the target template. An example of such templates can include, for example, viral, bacterial, or other pathogen sequences. In many embodiments, it is desirable to determine simply whether an individual (human or non-human animal) has a viral or other infection, regardless of the precise viral variant that has infected the individual. As an example, one can use a primer pair to amplify HCV using a polymerase of the invention and detect the presence of the HCV even if the particular virus infecting the individual has a mutation resulting in a mismatch at the primer hybridization site.
[0167] Target nucleic acids can come from a biological or synthetic source. The target can be, for example, DNA or RNA. Generally, where amplicons are generated, the amplicons will be composed of DNA, though ribonucleotides or synthetic nucleotides can also be incorporated into the amplicon. Where one wishes to detect an RNA, the amplification process will typically involve the use of reverse transcription, including for example, reverse transcription PCR (RT-PCR).
[0168] Specific target sequences can include, e.g., viral nucleic acids (e.g., human immunodeficiency virus (HIV), hepatitis virus B (HBV), (cytomegalovirus (CMV), parvo B19 virus, Epstein-Barr virus, hepatitis virus C (HCV), human papilloma virus (HPV), Japanese encephalitis virus (JEV), West Nile virus (WNV), St. Louis encephalitis virus (SLEV), Murray Valley encephalitis virus, and Kunjin virus), bacterial nucleic acids (e.g., S. aureus, Neisseria meningitidis, Plasmodium falciparum, Chlamydia muridarum, Chlamydia trachomatis), mycobacteria, fungal nucleic acids, or nucleic acids from animals or plants. In some embodiments, the target nucleic acids are animal (e.g., human) nucleic acids or are derived from an animal (e.g., human) sample (i.e., viral or other pathogenic organism nucleic acids may be present in a sample from an animal biopsy, blood sample, urine sample, fecal sample, saliva, etc.). In some embodiments, the target nucleic acids are, for example, human genetic regions that may include variants associated with disease (e.g., cancer, diabetes, etc.). Because in some embodiments the polymerases of the invention have mismatch tolerance, such enzymes are particularly useful, for example, where a diversity of related sequences could be in a target sequence. As an example, the invention can he used to detect viral pathogens, where the viral pathogens have sufficient variation in their genomes to make it difficult or impossible to design a single or small set of primers that will amplify most or all possible viral genomes or in cancer or other disease genetic markers where variation in sequence is known or likely to occur.
[0169] Other methods for detecting extension products or amplification products using the improved polymerases described herein include the use of fluorescent double-stranded nucleotide binding dyes or fluorescent double-stranded nucleotide intercalating dyes. Examples of fluorescent double-stranded DNA binding dyes include SYBR-green (Molecular Probes). The double stranded DNA binding dyes can be used in conjunction with melting curve analysis to measure primer extension products and/or amplification products. The melting curve analysis can be performed on a real-time PCR instrument, such as the ABI 5700/7000 (96 well format) or ABI 7900 (384 well format) instrument with onboard software (SDS 2.1). Alternatively, the melting curve analysis can be performed as an end point analysis. Exemplary methods of melting point analysis are described in U.S. Patent Publication No. 2006/0172324, the contents of which are expressly incorporated by reference herein in its entirety.
[0170] In another aspect of the present invention, kits are provided for use in primer extension methods described herein in some embodiments, the kit is compartmentalized for ease of use and contains at least one container providing an improved DNA polymerase in accordance with the present invention. One or more additional containers providing additional reagent(s) can also be included. In some embodiments, the kit can also include a blood collection tube, container, or unit that comprises heparin or a salt thereof or releases heparin into solution. The blood collection unit can be a heparinized tube. Such additional containers can include any reagents or other elements recognized by the skilled artisan for use in primer extension procedures in accordance with the methods described above, including reagents for use in, e.g., nucleic acid amplification procedures (e.g., PCR, RT-PCR), DNA sequencing procedures, or DNA labeling procedures. For example, in certain embodiments, the kit further includes a container providing a 5′ sense primer hybridizable, under primer extension conditions, to a predetermined polynucleotide template, or a primer pair comprising the 5′ sense primer and a corresponding 3′ antisense primer. In other, non-mutually exclusive variations, the kit includes one or more containers providing nucleoside triphosphates (conventional and/or unconventional). In specific embodiments, the kit includes alpha-phosphorothioate dNTPs, dUTP, MP, and/or labeled dNTPs such as, e.g., fluorescein- or cyanin-dye family dNTPs. In still other, non-mutually exclusive embodiments, the kit includes one or more containers providing a buffer suitable for a primer extension reaction.
[0171] In another aspect of the present invention, reaction mixtures are provided comprising the polymerases with increased reverse transcriptase efficiency, mismatch tolerance, extension rate and/or tolerance of RI and polymerase inhibitors as described herein. The reaction mixtures can further comprise reagents for use in, e.g., nucleic acid amplification procedures (e.g., PCR, RT-PCR), DNA sequencing procedures, or DNA labeling procedures. For example, in certain embodiments, the reaction mixtures comprise a buffer suitable for a primer extension reaction. The reaction mixtures can also contain a template nucleic acid (DNA and/or RNA), one or more primer or probe polynucleotides, nucleoside triphosphates (including, e.g., deoxyribonucleotides, ribonucleotides, labeled nucleotides, unconventional nucleotides), salts (e.g., Mn.sup.2+, Mg.sup.2+), labels (e.g., fluorophores). In some embodiments, the reaction mixtures contain a 5′-sense primer hybridizable, under primer extension conditions, to a predetermined polynucleotide template, or a primer pair comprising the 5′-sense primer and a corresponding 3′ antisense primer. In some embodiments, the reaction mixtures contain alpha-phosphorothioate dNTPs, dUTP, dTTP, and/or labeled dNTPs such as, e.g., fluorescein- or cyanin-dye family dNTPs. In some embodiments, the reaction mixtures comprise an iron chelator or a purple dye. In certain embodiments, the reaction mixtures comprise hemoglobin, or a degradation product of hemoglobin. For example, in certain embodiments, the degradation products of hemoglobin include heme breakdown products such as hemin, hematin, hematophoryn, and bilirubin. In other embodiments, the reaction mixtures comprise heparin or a salt thereof. In certain embodiments, the reaction mixture contains a template nucleic acid that is isolated from blood. In other embodiments, the template nucleic acid is RNA and the reaction mixture comprises heparin or a salt thereof.
EXAMPLES
[0172] The following examples are offered to illustrate, but not to limit the claimed invention.
Example 1
Library Generation
[0173] In brief, the steps in this screening process included library generation, expression and partial purification of the mutant enzymes, screening of the enzymes for the desired properties, DNA sequencing, clonal purification, and further characterization of selected candidate mutants. Each of these steps is described further below.
[0174] Clonal Library generation: A nucleic acid encoding the polymerase domain of Z05 D580G DNA polymerase was subjected to error-prone (mutagenic) PCR between Blp I and Bgl II restriction sites of a plasmid including this nucleic acid sequence. The amplified sequence is provided as SEQ ID NO:39. The primers used for this are given below:
TABLE-US-00002 Forward Primer: (SEQ ID NO: 30) 5′-CTACCTCCTGGACCCCTCCAA-3′; and, Reverse Primer: (SEQ ID NO: 31) 5′-ATAACCAACTGGTAGTGGCGTGTAA-3′
PCR was performed using a range of Mg.sup.2+ concentrations from 1.8-3.6 mM, in order generate libraries with a range of mutation rates. Buffer conditions were 50 mM Bicine pH 8.2, 115 mM KOAc, 8% w/v glycerol, and 0.2 mM each dNTPs, A GeneAmp® AccuRT Hot Start PCR enzyme was used at 0.15 U/μL. Starting with 5×10.sup.5 copies of linearized Z05 D580G plasmid DNA per reaction volume of 50 μL, reactions were denatured using a temperature of 94° C. for 60 seconds, then 30 cycles of amplification were performed, using a denaturation temperature of 94° C. for 15 seconds, an annealing temperature of 60° C. for 15 seconds, an extension temperature of 72° C. for 120 seconds, and followed by a final extension at a temperature of 72° C. for 5 minutes.
[0175] The resulting amplicon was purified with a QIAquick PCR Purification Kit (Qiagen, Inc., Valencia, Calif., USA) and cut with Blp I and Bgl II, and then re-purified with a QIAquick PCR Purification Kit. A Z05 D580G vector plasmid was prepared by cutting with the same two restriction enzymes and treating with alkaline phosphatase, recombinant (RAS, cat# 03359123001) and purified with a QIAquick PCR. Purification Kit. The cut vector and the mutated insert were mixed at a 1:3 ratio and treated with T4 DNA ligase for 5 minutes at room temperature (NEB Quick Ligation™ Kit). The ligations were purified with a QIAquick PCR Purification Kit and transformed into an E. coli host strain by electroporation.
[0176] Aliquots of the expressed cultures were plated on ampicillin-selective medium in order to determine the number of unique transformants in each transformation. Transformations were stored at −70° C. to −80° C. in the presence of glycerol as a cryo-protectant.
[0177] Each library was then spread on large format ampicillin-selective agar plates. Individual colonies were transferred to 384-well plates containing 2× Luria broth with ampicillin and 10% w/v glycerol using an automated colony picker (QPix2, Genetix Ltd): These plates were incubated overnight at 30° C. to allow the cultures to grow and then stored at −70° C. to −80° C. The glycerol added to the 2× Luria broth was low enough to permit culture growth and yet high enough to provide cryo-protection. Several thousand colonies at several mutagenesis (Mg.sup.2+) levels were prepared in this way for later use.
[0178] Extract library preparation Part 1—Fermentation: From the clonal libraries described above, a corresponding library of partially purified extracts suitable for screening purposes was prepared. The first step of this process was to make small-scale expression cultures of each clone. These cultures were grown in 96-well format; therefore there were 4 expression culture plates for each 384-well library plate. 0.5 μL was transferred from each well of the clonal library plate to a well of a 96 well seed plate, containing 150 μL of Medium A (see Table 3 below). This seed plate was shaken overnight at 1150 rpm at 30° C., in an iEMS plate incubator/shaker (ThermoElectron). These seed cultures were then used to inoculate the same medium, this time inoculating 20 μL, into 250 μL Medium A in large format 96 well plates (Nuns #267334). These plates were incubated overnight at 37° C. with shaking. The expression plasmid contained transcriptional control elements, which allow for expression at 37° C. but not at 30° C. After overnight incubation, the cultures expressed the clone protein at typically 1-10% of total cell protein. The cells from these cultures were harvested by centrifugation. These cells were either frozen (−20° C.) or processed immediately, as described below.
TABLE-US-00003 TABLE 2 Medium A (Filter-sterilized prior to use) Component Concentration MgSO.sub.4•7H.sub.2O 0.2 g/L Citric acid•H.sub.2O 2 g/L K.sub.2HPO.sub.4 10 g/L NaNH.sub.4PO.sub.4•4H.sub.2O 3.5 g/L MgSO.sub.4 2 mM Casamino acids 2.5 g/L Glucose 2 g/L Thiamine•HCl 10 mg/L Ampicillin 100 mg/L
[0179] Extract library preparation Part 2—Extraction: Cell pellets from the fermentation step were resuspended in 25 μL Lysis buffer (Table 3 below) and transferred to 384-well thermocycler plates and sealed. Note that the buffer contained lysozyme to assist in cell lysis, and DNase to remove DNA from the extract. To lyse the cells the plates were incubated at 37° C. for 15 minutes, frozen overnight at −20° C., and incubated again at 37° C. for 15 minutes. Ammonium sulfate was added (1.5 μL of a 2M solution) and the plates incubated at 75° C. for 15 minutes in order to precipitate and inactivate contaminating proteins, including the exogenously added nucleases. The plates were centrifuged at 3000×g for 15 minutes at 4° C. and the supernatants transferred to a fresh 384-well thermocycler plate. These extract plates were frozen at −20° C. for later use in screens. Each well contained about 0.5-3 μM of the mutant library polymerase enzyme.
TABLE-US-00004 TABLE 3 Lysis Buffer Component Concentration or Percentage Tris pH 7.5 50 mM EDTA 1 mM MgCl.sub.2 6 mM Tween 20 0.5% v/v Lysozyme (from powder) 1 mg/mL DNase I 0.05 Units/μL
Example 2
Identification of Mutant DNA Polymerases With Improved Reverse Transcription Efficiency
[0180] Screening extract libraries for improved reverse transcription efficiency: The extract library was screened by comparing Cp (Crossing Point) values from growth curves generated by fluorescent 5′ nuclease (TaqMan) activity of crude enzyme extracts in a RT-PCR system from amplification of a 240 base pair amplicon from Hepatitis C Virus (HCV) transcript JP2-5, containing the first 800 bases of HCV genotype Ib 5′NTR in pSP64 poly(A) (Promega),
[0181] Reactions were carried out on the Roche LC 480 kinetic thermocycler in 384 well format with each well containing 1.5 μL of an individual enzyme extract diluted 5-fold with buffer containing 20 mM Tris-HCl, pH 8, 100 mM KCl, 0.1 mM EDTA, and 0.1% Tween-20 added to 18.5 μL of RT-PCR master mix described in Table 4. The thermocycling conditions were: 1 minute at 65° C. (“RT” step); 5 cycles of 94° C. for 15 seconds followed by 60° C. for 30 seconds; and 45 cycles of 91° C. for 15 seconds followed by 60° C. for 30 seconds.
TABLE-US-00005 TABLE 4 Component Concentration Tricine pH 8.3 50 mM KOAc 100 mM Glycerol 5% (v/v) DMSO 2% (v/v) Primer 1 200 nM Primer 2 200 nM TaqMan Probe 75 nM Aptamer 200 nM dATP 200 μM dCTP 200 μM dGTP 200 μM dUTP 400 μM UNG .04 Units/μL RNA Target 5000 copies/μL Mn(OAc).sub.2 2.1 mM
[0182] Approximately 5000 clones were screened using the above protocol. Twenty one clones were chosen from the original pool for rescreening based on earliest Crossing Point (Cp) values and fluorescent plateau values above an arbitrary cut off as calculated by the Abs Quant/2.sup.nd derivative max method. Culture wells corresponding to the top extracts were sampled to fresh growth medium and re-grown to produce new culture plates containing the best mutants, as well as a number of parental Z05 D580X (X=G, K, and R) cultures to be used for comparisons. These culture plates were then used to make fresh crude extracts which were quantified and rescreened at 20 nM concentrations with the same master mix conditions as described in Table 4. Table 5 shows the Cp values obtained from the FAM signal increase due to cleavage of the TaqMan probe. Results show that clone 0818-M22 amplifies the RNA target with higher efficiency than the Z05 D580G parental.
TABLE-US-00006 TABLE 5 Cp values of Amplification of HCV transcript JP2-5 Clone Average Cp 0818-M22 19.2 Z05 D580R 24.0 Z05 D580K 24.5 Z05 D580G 27.5
[0183] The DNA sequence of the mutated region of the polymerase gene was sequenced to determine the mutation(s) that were present in any single clone. Clone 0818-M22 was chosen for further testing, so mutant polymerase protein was expressed in flask culture, purified to homogeneity, and quantified.
[0184] Use of Z05 D580G mutant in Mn.sup.2+-based RT-PCR: Sequencing results revealed that clone 0818-M22 carries mutations E522G, N545Y,and T6421 in addition to the parental D580G mutation. Purified mutant Z05 D580G_E522G_N545Y_T642I (0818-M22) was compared to parental Z05 D580G in TaqMan Mn.sup.2+-based RT-PCR. Reverse transcription and PCR efficiencies were measured by comparing Cp values from amplifications of JP2-5 RNA transcript and pJP2-5 DNA linear plasmid digested with the restriction endonuclease EcoRI. Oligonucleotides and Master Mix conditions (Table 4) were the same as used in the original screen. Each reaction had either 100,000 copies of JP2-5 transcript, 100,000 copies of pJP2-5 linear plasmid DNA, or 1000 copies of pJP2-5 linear plasmid DNA. All targets were amplified with Primer 1 and Primer 2, as described above, in duplicate reactions to generate a 240 base pair amplicon. All reactions were performed on the Roche Light Cycler 480 thermal cycler with a reaction volume of 15 93 L. Crossing Points (Cps) were calculated by the Abs Quant/2.sup.nd derivative max method and averaged. Amplifications were carried out using a range of DNA polymerase concentrations from 2.5 nM-30 nM. Thermocycling conditions were: 1 minute at 65° C. (“RT” step); 5 cycles of 94° C. for 15 seconds followed by 60° C. for 30 seconds; and 45 cycles of 91° C. for 15 seconds followed by 60° C. for 30 seconds. Table 6 shows Cp values obtained from fluorescent signal increase due to cleavage of the TaqMan probe at 20 nM enzyme condition.
TABLE-US-00007 TABLE 6 Cp values of Amplification of HCV JP2-5 RNA and pJP2-5 DNA RNA 10.sup.5 DNA 10.sup.5 DNA 10.sup.3 Enzyme copies Cp copies Cp copies Cp Z05 D580G 31.6 19.7 27.5 Z05 D580G_E522G_N545Y_T642I 20.7 19.0 26.7
[0185] The results indicate that mutant Z05 D580G_E522G_N545Y_T6421 allows for more efficient amplification of RNA target without compromise of PCR efficiency on DNA target, as compared to parental.
[0186] Use of Z05 D580G mutant in Me.sup.2+-based RT-PCR: The purified mutant Z05 D580G_E522G_N545Y_T6421 was also compared to parental Z05 D580G for the ability to perform TaqMan RT-PCR in the presence of Mg.sup.2+. The master mix conditions used were identical to those described in Table 4, except that the KOAc concentration was varied from 20 mM-160 mM and Mn(OAc).sub.2 was replaced with 2.1 mM Mg(OAc).sub.2. Each reaction had 30 nM enzyme and either 100,000 copies of JP2-5 transcript, 100,000 copies of pJP2-5 linear plasmid DNA, or 1000 copies of pJP2-5 linear plasmid DNA. All targets were amplified with the same primer set in duplicate reactions to generate a 240 base pair amplicon. PCR and RT-PCR efficiencies were determined by comparing Cp values between DNA and RNA. All reactions were performed on the Roche Light Cycler 480 thermal cycler with a reaction volume of 15 μL. Crossing Points (Cps) were calculated by the Abs Quant/2.sup.nd derivative max method and Cps were averaged. Thermocycling conditions were: 65° C.-5 minutes, 70° C.-5 minutes, and 75° C.-5 minutes (three temperature “RT” step); 5 cycles of 94° C. for 15 seconds followed by 62° C. for 30 seconds; and 45 cycles of 91° C. for 15 seconds followed by 62° C. for 30 seconds. Table 7 shows Cp values obtained from fluorescent signal increase due to cleavage of the TaqMan probe at the 40 nM KOAc condition.
TABLE-US-00008 TABLE 7 Cp values of Amplification of HCV JP2-5 RNA and pJP2-5 DNA RNA 10.sup.5 DNA 10.sup.5 DNA 10.sup.3 Enzyme copies Cp copies Cp copies Cp Z05 D580G 28.4 18.5 24.7 Z05 D580G_E522G_N545Y_T642I 21.7 17.7 23.8
[0187] The results indicate that mutant Z05 D580G_E522G_N545Y_T642I performs Mg.sup.2+-based RT PCR with significantly greater efficiency than Z05 D580G under these conditions.
[0188] Determination of phenotype-conferring mutation(s): The mutant 0818-M22 displays significant improvement in RNA amplification over parental Z05 D580G in the RT-PCR screen. Clone 0818-M22 is a triple mutant carrying mutations E522G, N545Y, and T6421 in addition to the parental D580G mutation. Based on the nature of the amino acid change, we predicted that the E522G mutation is responsible for the observed phenotype. A Z05 D580Q_E522G mutant was constructed by subcloning, purified, quantified, and compared to 0818-M22 (Z05 D580G_E522G_N545Y_T642I) and parental Z05 D580G in Mn.sup.2− activated TaqMan RT-PCR with varying enzyme concentrations from 5 nM-40 nM. Master Mix conditions were the same as those described previously in Table 4 except 90 mM KOAc was used instead of 100 mM. Each reaction had either 100,000 copies of JP2-5 transcript, 100,000 copies of pJP2-5 linear plasmid DNA, or 1000 copies of pJP2-5 linear plasmid DNA. All targets were amplified with the same primer set in duplicate reactions to generate a 240 base pair amplicon. The PCR and RT-PCR efficiencies were determined by comparing Cp values between DNA and RNA. All reactions were performed on the Roche Light Cycler 480 thermal cycler with a reaction volume of 15 μL. Crossing Points (Cps) were calculated by the Abs Quant/2.sup.nd derivative max method and Cps were averaged. The thermocycling conditions were: 65° C.-1 minute (“RT” step); 5 cycles of 94° C. for 15 seconds followed by 60° C. for 30 seconds; and 45 cycles of 91° C. for 15 seconds followed by 60° C. for 30 seconds. Table 8 shows the Cp values obtained from fluorescent signal increase due to cleavage of the TaqMan probe at the 30 nM enzyme condition.
TABLE-US-00009 TABLE 8 Cp values of Amplification of HCV JP2-5 RNA and pJP2-5 DNA RNA 10.sup.5 DNA 10.sup.5 DNA 10.sup.3 Enzyme copies Cp copies Cp copies Cp Z05 D580G 26.0 18.3 25.7 Z05 D580G_E522G_N545Y_T642I 21.2 18.1 25.4 Z05 D580G_E522G 21.6 18.2 25.5
[0189] This example demonstrates that the Z05 :D580G_E522G_N545Y_T642I and Z05 D580G_E522G mutations have similar Cp values on both RNA and DNA targets, demonstrating that the E522G mutation confers the observed improvement in RT-PCR performance.
Example 3
Isolation of E522G Mutation
[0190] The E522G mutation was subcloned into Z05 DNA polymerase backbone as a single mutant. After expression and purification, RT-PCR efficiencies of mutant Z05 E522G were compared with DNA polymerases Z05, Z05 D580G, and Z05 D580G E522G in Mn.sup.2− catalyzed TaqMan RT-PCR. Master Mix conditions were the same as those described previously in Table 4, except Mn(OAc).sub.2 concentration was 1.5 mM, UNG concentration was 0.2 U/μL, potassium acetate concentration was 120 mM, and probe concentration was 100 nM. Each reaction had a final enzyme concentration of 20 nM in a total reaction volume of 15 μL. Each reaction had either 100,000 copies of JP2-5 transcript, 100,000 copies of pJP2-5 linear plasmid DNA, or 1000 copies of pJP2-5 linear plasmid DNA. All targets were amplified with the same primer set in replicates of four reactions to generate a 240 base pair amplicon. All reactions were performed on the Roche Light Cycler 480 thermal cycler. Crossing Point (Cp) values were calculated by the Abs Quant/2.sup.nd derivative max method and averaged. The RT-PCR thermal profile was: 2 minutes at 50° C. (“UNG” step); 55° C.-1 minute, 60° C.-2 minutes, and 65° C.-3 minutes (three temperature “RT” step); 5 cycles of 94° C. for 15 seconds followed by 62° C. for 30 seconds; and 45 cycles of 91° C. for 15 seconds followed by 62° C. for 30 seconds. Table 9 shows the Cp values obtained from fluorescent signal increase due to cleavage of the TaqMan probe.
TABLE-US-00010 TABLE 9 Cp values of Amplification of HCV JP2-5 RNA and pJP2-5 DNA RNA 10.sup.5 DNA 10.sup.5 DNA 10.sup.3 Enzyme copies Cp copies Cp copies Cp Z05 33.6 17.6 25.3 Z05 D580G 20.0 17.2 24.8 Z05 E522G 20.8 17.2 24.9 Z05 D580G E522G 19.5 17.1 25.0
[0191] This example demonstrates that the E522G mutation provides increased RT-PCR efficiency independently of the D580G mutation. Further, the Cp values of the E552G enzyme were similar to the Z05 parent enzyme when amplifying a DNA template. Thus, the E522G mutation provides increased RT-PCR efficiency without a decrease in polymerase efficiency when amplifying a DNA template.
[0192] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, sequence accession numbers, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.